PMI BioPharma Solutions, a contract development and manufacturing organization (CDMO) providing drug discovery, development, and manufacturing services, has received funding from Oak HC/FT to expand its capabilities to become a specialized, one-stop-shop CDMO for clinical and commercial injectable therapies. PMI also unveiled its rebranding to August Bioservices and has augmented the company’s expertise with the appointment of several industry executives to its leadership team. The new funding and expanded leadership team position August Bioservices to deliver best-in-class and highly flexible capabilities that span the research and development continuum and scale with customers’ needs.
 
The company is currently exploring sites to build a state-of-the-art facility, which will expand its capabilities to include sterile fill-finish and lyophilization for late stage clinical and commercial work. These new capabilities will complement August Bioservices’ full range of contract services for customers in the pharmaceutical and biotechnology space.
 
The company also announced several senior appointments, including Jenn Adams as chief executive officer; Mats Bjoerkman as chief financial officer; Joe Mase as executive vice president of operations; and Brad Leach as senior vice president of commercial development.

“I’m thrilled to lead August Bioservices at such an important time in the company’s growth,” said Jenn Adams, the new chief executive. “Our new funding, leadership team, and rebrand mark a turning-period for the company as we look to advance our customers’ drug discovery, development and manufacturing projects. Our leading research and development platform, combined with growing demand from our pharmaceutical and biotechnology customers for expanded manufacturing services, provides a solid foundation to grow and scale our capabilities.”
 
Prior to joining August Bioservices, Adams was senior vice president and president for the clinical product solutions business at AmerisourceBergen and has served in healthcare leadership positions for more than 30 years. She has extensive experience leading, transforming, and driving growth in both Fortune 500 public and private equity-backed companies.
 
“We’re excited to invest in the growth of August Bioservices and continue our long-time partnership with Jenn as she accelerates the company’s path to success,” said Andrew Adams, co-founder and managing partner, Oak HC/FT. “The opportunity ahead of August is immense given the growth and size of the sterile injectables manufacturing category and increasing mix of complex therapies that require injectable formulation. With new funding and a top-tier team of life science experts, August Bioservices is well positioned to serve the large and growing need in the market.”